Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma

Urology

Volumn 56, Issue 4, 2000, Pages 689-695

  Franke, Knut H ^a   Miklosi, Mario ^a,b   Goebell, Peter ^a   Clasen, Sonja ^a   Steinhoff, Christine ^a   Anastasiadis, Aristoteles G ^a   Gerharz, Claus Dieter ^a   Schulz, Wolfgang A ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Derer 's University Hospital Slovakia   (Slovakia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; TUMOR MARKER;

ARTICLE; BLADDER TUMOR; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SUPERFICIAL CANCER; UROGENITAL TRACT CANCER;

AGED; CARCINOMA; CARCINOMA IN SITU; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 0033833891     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00678-6     Document Type: Article

References (27)

1. Loda M., Cukor B., Tam S.W., et al. Increased proteasome-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 3:1997;231-234.
2. KIP1 protein prognostic implications in primary breast cancer . Nat Med. 3:1997;227-230.
3. KIP1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58:1998;542-548.
4. 1-phase progression . Genes Dev. 13:1999;1501-1512.
5. KIP1 induces cell migration . Nat Med. 4:1998;1449-1452.
6. Gonzalez-Zulueta M., Bender C.M., Yang A.S., et al. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:1995;4531-4535.
7. Kai M., Arakawa H., Sugimoto Y., et al. Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. Jpn J Cancer Res. 86:1995;249-251.
8. Orlow I., Lacombe L., Hannon G.J., et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst. 87:1995;1524-1529.
9. 1→S transition regulatory molecules in human urothelial cancer. Jpn J Cancer Res. 89:1998;719-726.
10. WAF1/CIP1 in primary bladder tumors. Oncol Res. 8:1996;409-414.
11. WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene. 13:1996;1831-1837.
12. Clasen S., Schulz W.A., Gerharz C.-D., et al. Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer. 77:1998;515-521.
13. Lipponen P., Aaltomaa S., Eskelinen M., et al. Expression of p21 (waf1/cip1) protein in transitional cell bladder tumours and its prognostic value. Eur Urol. 34:1998;237-243.
14. WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 90:1998;1072-1079.
15. Mostofi F.K., Sorbin L.H., Torloni H. Histological Typing of Urinary Bladder Tumors. 1973;World Health Organization, Offset Publication No. 10. Geneva.
16. Hermanek P., Sobin L.H. TNM Classification of Malignant Tumours. 4th ed. 1992;160-162 Springer, Berlin.
17. Koss L.G. Tumors of the urinary bladder. Firminper H.I. Atlas of Tumor Pathology. 1975;62-67 Armed Forces Institute of Pathology, Washington, DC.
18. Peto R., Pyke M.C., Armatage N.E. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 35:1977;53-58.
19. Schulz W.A., Jankevicius F., Gerharz C.D., et al. Predictive value of molecular alterations for the prognosis of urothelial carcinoma. Cancer Detect Prev. 22:1998;422-429.
20. Tsihlias J., Kapusta L., Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med. 50:1999;401-423.
21. Makri D., Schulz W.A., Grimm M., et al. WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. Int J Oncol. 12:1998;621-628.
22. LaBaer J., Garrett M.D., Stevenson L.F., et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:1997;847-862.
23. KIP1. J Clin Invest. 103:1999;597-604.
24. Wang J., Walsh K. Resistance to apoptosis conferred by CDK inhibitors during myocyte differentiation. Science. 273:1996;359-361.
25. WAF/CIP protein expression in muscle invasive bladder cancer. Oncol Rep. 6:1999;687-693.
26. KIP1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res. 59:1999;3245-3250.
27. KIP1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 155: 1129-1136, 1999.